Optimal Infliximab Dosing for Suboptimal Drug Levels in Crohn's Disease with Perianal Symptoms

Standard Dosing Framework

The American Gastroenterological Association recommends a dose escalation to 10 mg/kg every 8 weeks for patients who initially respond but subsequently lose response to infliximab, as seen in patients with Crohn's disease and perianal symptoms 1

Target trough levels are typically 3-7 μg/mL for maintenance of remission in Crohn's disease, though optimal levels depend on clinical context and assay used, according to the European Crohn’s and Colitis Organisation 2, 1
With active perianal symptoms despite a level of 7.2 μg/mL, this suggests either inadequate drug exposure for fistulizing disease or a need for higher therapeutic targets, as noted by the British Society of Gastroenterology 3, 1
Fistulizing Crohn's disease may require higher trough levels than inflammatory disease alone, as recommended by the American College of Gastroenterology 3

The British Society of Gastroenterology recommends increasing to 10 mg/kg every 8 weeks rather than shortening the interval to every 6 weeks for patients with suboptimal infliximab levels and ongoing symptoms 1
Doubling the dose (10 mg/kg every 8 weeks) is generally more convenient and cost-effective than interval shortening, as suggested by the National Institute for Health and Care Excellence 1

In patients with low drug levels and negative/low antibodies, dose increase is the preferred strategy, according to the British Society of Gastroenterology 1
Interval shortening to 6 weeks may be as effective as shortening to 4 weeks or giving 10 mg/kg, but the standard approach is 10 mg/kg every 8 weeks, as recommended by the American Gastroenterological Association 1
A retrospective study showed sustained response in 50% receiving 10 mg/kg every 8 weeks versus 39% with interval shortening (OR 1.5, 95% CI 0.8-2.9), providing moderate evidence for this approach 1

After dose optimization, reassess clinical response at 8-12 weeks and repeat therapeutic drug monitoring to confirm adequate trough levels (target >7-10 μg/mL for fistulizing disease), as recommended by the European Crohn’s and Colitis Organisation 2, 1
If remission is achieved and maintained for 3-4 months, consider whether dose can be reduced back to standard dosing, according to the American College of Gastroenterology 1
Continue monitoring for perianal fistula closure, which may take several months even with optimized therapy, as noted by the British Society of Gastroenterology 3

The European Crohn's and Colitis Organisation (ECCO) strongly recommends infliximab as maintenance therapy for moderate-to-severe Crohn's disease with documented disease control 4
The patient meets continuation criteria for infliximab therapy based on documented clinical response, including symptom improvement, reduced rectal bleeding, and endoscopic evidence of mild inflammation 4, 5
The British Society of Gastroenterology and Canadian Association of Gastroenterology recommend using therapeutic drug monitoring to guide dose optimization 4

The FDA-approved maintenance regimen for Crohn's disease is infliximab 5mg/kg every 8 weeks, with dose escalation to 10mg/kg every 8 weeks permitted for patients who respond but then lose response 4
Dose intensification options, such as increasing the dose to 10mg/kg every 8 weeks or shortening the interval, are recommended for patients with suboptimal response 4

The medically appropriate regimen is Inflectra 10mg/kg every 8 weeks, not every 4 weeks, with therapeutic drug monitoring to guide dose optimization 4
Adding an immunomodulator, such as azathioprine or methotrexate, should be strongly considered to reduce immunogenicity and improve long-term outcomes 5, 4, 6

Infection screening, laboratory monitoring, and drug level monitoring are essential for continued therapy 4
Specialist management, including continued gastroenterology follow-up, meets prescriber requirements 4